ABOUT INDEXING BOARD ARCHIVES AUTHOR GUIDELINES SUBMIT PAPER AUTHORS'S SUBSCRIPTIONS AUTHORS'S PAGE PUBLISHING ETHICS NEWS, EVENTS
REVISTA DE CHIMIE
https://doi.org/10.37358/Rev.Chim.1949

OSIM Nr. R102355
ISSN 0034-7752
ISSN 2668-8212 (Online)
Journal Metrics
* Impact Factor 2018-19: 1.605
* 5-Year IF: 1.34
* CiteScore: 1.23
* SNIP: 0.710
* SJR: 0.294
(academic-accelerator.com)
Crossref Member Badge
 DOI  logo

Chemistry Magazine

LATEST ISSUE >>>

   Volume 71, 2020
   Volume 70, 2019
   Volume 69, 2018
   Volume 68, 2017
   Volume 67, 2016
   Volume 66, 2015
   Volume 65, 2014
   Volume 64, 2013
   Volume 63, 2012
   Volume 62, 2011
   Volume 61, 2010
   Volume 60, 2009
   Volume 59, 2008
   Volume 58, 2007
   Volume 57, 2006
   Volume 56, 2005
   Volume 55, 2004
   Volume 54, 2003
   Volume 53, 2002
 
<<<< back

Revista de Chimie, Volume 71, Issue 1, pp. 140-144 (2020)
https://doi.org/10.37358/RC.20.1.7824

Andreea-Daniela Gheorghe, Daniela Zob, Dana-Lucia Stanculeanu

Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer

Abstract:

Even with the decreasing incidence of colorectal cancer (CRC), data showing that the rate of incidence of CRC is declining with 2.9% every year starting with 2005 until 2014, CRC remains one of the most frequent neoplasia all over the world. Almost a quarter of patients with CRC present with stage IV disease at diagnosis and nearly 30% of patients with localized disease will progress within 5 years. Our study included 129 patients with metastatic CRC that received chemotherapy ± bevacizumab, from January 2017 until December 2018. Patients received fluropirimidine-based chemotherapy plus or minus bevacizumab. No significant differences was registered between groups with respects of age, sex, tumor localization, chemotherapy regimen used. Also no significant difference was found in our groups regarding risk factors for bleeding and medical history. No remarkable differences were registered between the two groups regarding common adverse reactions to chemotherapy, with the exception of physical asthenia which was found in a greater proportion of patients that received bevacizumab in combination with chemotherapy. In our study most frequent adverse events related to bevacizumab were grade 1 or 2, only few adverse events were grade 3 or 4 and lead to discontinuation of bevacizumab treatment, and these were mainly thromboembolic events and bleeding.
Keywords:
metastatic colorectal cancer; bevacizumab; chemotherapy; adverse events

Issue: 2020 Volume 71, Number 1
Pages: 140-144
https://doi.org/10.37358/RC.20.1.7824
download pdf   Download Pdf Article
Citation Styles
Cite this article as:
GHEORGHE, A., ZOB, D., STANCULEANU, D., Rev.Chim., 71, no. 1, 2020, p. 140

Vancouver
Gheorghe A, Zob D, Stanculeanu D. Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer. Rev. Chim.[internet]. 2020 Jan;71(1):140-144. Available from: https://doi.org/10.37358/RC.20.1.7824


APA 6th edition
Gheorghe, A., Zob, D. & Stanculeanu, D. (2020). Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer. Revista de Chimie, 71(1), 140-144. https://doi.org/10.37358/RC.20.1.7824


Harvard
Gheorghe, A., Zob, D., Stanculeanu, D. (2020). 'Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer', Revista de Chimie, 71(1), pp. 140-144. https://doi.org/10.37358/RC.20.1.7824


IEEE
A. Gheorghe, D. Zob, D. Stanculeanu, "Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer". Revista de Chimie, vol. 71, no. 1, pp. 140-144, 2020. [online]. https://doi.org/10.37358/RC.20.1.7824


Text
Andreea-Daniela Gheorghe, Daniela Zob, Dana-Lucia Stanculeanu,
Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer,
Revista de Chimie,
Volume 71, Issue 1,
2020,
Pages 140-144,
ISSN 2668-8212,
https://doi.org/10.37358/RC.20.1.7824.
(https://revistadechimie.ro/Articles.asp?ID=7824)
Keywords: metastatic colorectal cancer; bevacizumab; chemotherapy; adverse events


RIS
TY - JOUR
T1 - Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer
A1 - Gheorghe, Andreea-Daniela
A2 - Zob, Daniela
A3 - Stanculeanu, Dana-Lucia
JF - Revista de Chimie
JO - Rev. Chim.
PB - Revista de Chimie SRL
SN - 2668-8212
Y1 - 2020
VL - 71
IS - 1
SP - 140
EP - 144
UR - https://doi.org/10.37358/RC.20.1.7824
KW - metastatic colorectal cancer
KW - bevacizumab
KW - chemotherapy
KW - adverse events
ER -


BibTex
@article{RevCh2020P140,
author = {Gheorghe Andreea-Daniela and Zob Daniela and Stanculeanu Dana-Lucia},
title = {Adverse Events of Bevacizumab in Patients with Metastatic Colorectal Cancer},
journal = {Revista de Chimie},
volume = {71},
number = {1},
pages = {140-144},
year = {2020},
issn = {2668-8212},
doi = {https://doi.org/10.37358/RC.20.1.7824},
url = {https://revistadechimie.ro/Articles.asp?ID=7824}
}
 
Views number: 44    |     Downloads number: 0  
<<<< back
 
PUBLISHING SECTION
Author Guidelines
 * Ghidul Autorului (ro)
 * Paper Drafting
 * Paper Template
 * Paper Submission
 * Author Payments
 * Publishing Ethics
Submit Paper
Author's Page
  Search Authors
  News, Events
 chimie
*REVISTA DE CHIMIE - 70 de ani de aparitie neintrerupta*

Un eveniment special pentru comunitatea stiintifica din Romania va fi organizat in data de
4 martie 2020
Hotel Hilton Athenee Palace Bucuresti
Sala Regina Maria
ora 9.30.

Va asteptam.
 Chemistry Conferences Conferences of Contemporary Chemistry
 Publicatii de Chimie Publicatii de Chimie in Romania.
Scurt istoric
 BIBLIOTECA CHIMIEI Biblioteca Chimiei
 Materiale Plastice Materiale Plastice